Table 1.

Demographic and clinical characteristics of the patients enrolled in the study.

Cases	Age	Gender	Underlying conditions	Acquired source	Infectious foci	Empirical antibiotic therapies	Applied procedures (duration)
1	4 months	Female	None	Community	UTI	Cefuroksime	-
2	1 years	Male	imperforate anus	Hospital	Primary bacteremia	Ceftazidime	TPN (3 days)
3	23 days	Male	duodenal atresia	Hospital	Primary bacteremia	Cefotaxime, Amikacin	TPN (8 days)
4	3 years	Male	None	Community	Primary bacteremia	Cefotaxime	-
5	10 years	Female	ALL, neutropenia	Hospital	CR-BSI	Piperacillin/tazobactam	CVC (30 days)
6	12 years	Male	PSAGN	Community	Primary bacteremia	Cefuroxime	-
7	4 years	Male	Burn injury	Hospital	CR-BSI	Meropenem, Amikacin	MV (10 days), CVC (22 days)
8	8 years	Female	ALL, neutropenia	Hospital	Primary bacteremia	Piperacillin/tazobactam	-
9	18 days	Male	prematurity	Community	Primary bacteremia	Ampicillin, Amikacin	-
10	8 days	Female	prematurity	Hospital	Primary bacteremia	Meropenem, Vancomycin	TPN (8 days)
11	7 years	Female	None	Community	Primary bacteremia	Cefuroxime	-
12	10 years	Male	None	Community	CNS	Cefotaxime, Vancomycin	-
13	9 years	Male	Down syndrome	Community	Primary bacteremia	Meropenem, Vancomycin	-
14	1 month	Male	None	Community	Primary bacteremia	Ampicillin/sulbactam	-
15	12 years	Female	None	Hospital	Primary bacteremia	Piperacillin/tazobactam	-
16	1 month	Female	None	Community	Primary bacteremia	Ampicillin/sulbactam	-
17	11 years	Male	None	Hospital	Primary bacteremia	Meropenem	-
18	4 years	Male	ALL, neutropenia	Hospital	Primary bacteremia	Piperacillin/tazobactam	CVC (96 days)
19	15 years	Female	None	Community	Primary bacteremia	Cefotaxime	-
20	1 years	Female	None	Community	Primary bacteremia	Cefuroxime	-
21	5 years	Male	ALL, neutropenia	Hospital	Primary bacteremia	Piperacillin/tazobactam	-
22	3 days	Male	None	Community	Primary bacteremia	Ampicillin, Amikacin	-
23	23 days	Male	None	Community	Primary bacteremia	Ampicillin/sulbactam	-
24	27 days	Female	None	Hospital	Primary bacteremia	Meropenem	-